In vitro absorption studies and their relevance to absorption from the GI tract

Drug Development and Industrial Pharmacy

Volumn 23, Issue 9, 1997, Pages 879-892

  Ungell, Anna Lena ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Biological absorption methods; Biophysical absorption methods; Drug absorption; In vitro absorption methods; Method comparison; Mucosal integrity; Permeability methods

Indexed keywords

AMINO ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARRIER PROTEIN; CEPHALOSPORIN DERIVATIVE; FLUINDOSTATIN; FOSFOMYCIN; PEPTIDE; PHENAZONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SALICYLIC ACID DERIVATIVE; VACCINE;

BIOAVAILABILITY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG SOLUBILITY; GASTROINTESTINAL ABSORPTION; HUMAN; INTERMETHOD COMPARISON; MEMBRANE PERMEABILITY; NONHUMAN; PARTITION COEFFICIENT; PHYSICAL PARAMETERS; REVIEW;

EID: 0030964577     PISSN: 03639045     EISSN: None     Source Type: Journal    
DOI: 10.3109/03639049709148694     Document Type: Review

References (89)

1. A.-L. Ungell in Current Status on Targeted Drug Delivery to the Gastrointestinal Tract, Capsugel Library Symposia Series, 1993, p. 79.
2. C. J. Dakas, and P. G. Takla, Epitheo Klin Farmakol Farmakokinet Int., 5th ed., 1991, p. 124.
3. R. T. Borchardt, P. L. Smith, and G. Wilson, Models for Assessing Drug Absorption and Metabolism, Plenum Press (1996).
4. T. T. Kararli, Crit. Rev. Ther. Drug. Carrier Sys., 6. 39 (1989).
5. M. A. Navia and P. R. Chaturvedi, Drug Discov. Today: Res. Focus Rev. 1, 179 (1996).
6. P. Wils, A. Warnery, V. Phung-Ba, S. Legrain, and D. J. Scherman, Pharmacol. Exp. Therap., 269 654 (1994).
7. A. Lindahl, R. Sandström, A.-L. Ungell, B. Abrahamsson, T. Knutson, L. Knutson, and H. Lennernäs. Clin. Pharmacol. Ther., 60, 1 (1996).
8. P. S. Burton, R. A. Conradi, A. R. Hilgers, N. F. H. Ho, and L. L. J. Maggiora, Control. Rel. 19, 87 (1992).
9. K. Palm, K. Luhtman, A.-L. Ungell, G. Strandlund, and P. J. Artursson, Pharm. Sci., 85, 32 (1996).
10. P. Artursson, K. Palm, and K. Luhtman, Adv. Drug Del. Rev. (1997), (in press).
11. R. F. Rekker, and R. Mannhold, Calculations of Drug Lipophilicity, VCH Publishers, Weinheim, New York, Basel, Cambridge, 1992.
12. D. H. Leahy, J. Lynch, and D. C. Taylor, in Novel Drug Delivery, (Prescott and Nimmo, eds.), Wiley & Sons, New York, 1989, p. 33.
13. A. Leo, P. Y. C. Jow, C. Silipo, and C. Hansch, J. Med. Chem., 18, 865 (1975).
14. D. C. Kim, P. S. Burton, and R. T. Borchardt, Pharm. Res., 10, 1710 (1993).
15. E. Yodoya, K. Uemura, T. Tenma, T. Fujita, M. Murakami, A. Yamamoto, and S. Muranishi, J. Pharmacol. Exp. Therap. 27, 1509 (1994).
16. C. Pidgeon, S. Ong, H. Liu, X. Qiu, M. Pidgeon, A. H. Dantzig, J. Munroe, W. J. Hornback, J. S. Kasher, L. Glunz, and T. Szczerba, J. Med. Chem., 38, 590 (1995).
17. V. Merino, J. Freixas, M. del Val Bermejo, T. M. Garrigues, J. Moreno, and J. M. Pla-Delfina, J. Pharm. Sci., 84, 777 (1995).
18. M. J. Rathbone, and I. G. Tucker, Adv. Drug Del. Rev. 12, 41 (1991).
19. M. D. Perez-Buendia, B. Gomez-Perez, and J. M. Pla-Delfina, Arzneimittelforschung, 43, 789 (1993).
20. D. M. Oh, R. L. Curl, and G. L. Amidon, Pharm. Res. 10, 264 (1993).
21. M. Kessler, O. Acuto, C. Storelli, H. Murer, M. Muller, and G. Semenza, Biochim. Biophys. Acta, 506, 136 (1978).
22. H. Yuasa, G. L. Amidon, and D. Fleischer, Pharm. Res., 10, 400 (1993).
23. T. Ishizawa, S. Sadahiro, K. Hosoi, I. Tamai, T. Terasaki, and A. Tsuji, J. Pharmacobio-Dynamics, 15, 481 (1992).
24. I. Osiecka, P. A. Porter, R. T. Borchardt, J. A. Fix, and C. R. Gardner, Pharm. Res., 284 (1985).
25. P. A. Porter, I. Osiecka, R. T. Borchardt, J. A. Fix, L. Frost, and C. R. Gardner, Pharm. Res., 293 (1985).
26. A. B. R. Thomson, M. Keelan, M. T. Clandinin, and K. Walker, J. Clin. Invest., 77, 279 (1986).
27. A.-L. Ungell, S. Nylander, S. Bergstrand, Å Sjöberg, and H. Lennernäs, J. Pharm. Sci. (1977), (submitted for publication).
28. J. S. Kim, R. L. Oberle, D. A. Krummel, J. B. Dressman, and D. Fleischer, J. Pharm. Sci., 83, 1350 (1994).
29. P. S. Leppert, and J. A. Fix, J. Pharm. Sci., 83, 976 (1994).
30. T. H. Wilson and G. Wiseman, J. Physiol., 123, 116 (1954).
31. R. R. Levine, W. F. McNary, P. J. Kornguth and R. LeBlanc, Europ. J. Pharmacol., 9, 211 (1970).
32. P. Artursson, J. Pharm. Sci., 79, 476 (1990).
33. I. J. Hildalgo, T. J. Raub, and R. T. Borchardt, Gastroenterology, 96, 736.
34. T. Y. Ma, D. Hollander, D. Bhalla, H. Nguyen, and P. Krugliak, J. Lab. Clin. Med., 120, 329 (1992).
35. P. Wils, A. Warnery, V. Phung-Ba, and D. Scherman, Cell Biol. Toxicol. 10, 393 (1994).
36. R. Borchardt, in Peptides, Theoretical and Practical Approaches to Their Delivery, Capsugel Library Symposia Series, 1991, p. 9.
37. P. Artursson, A.-L. Ungell, and J.-E. Löfroth, Pharm. Res., 10, 1123 (1993).
38. E. Walter, T. Kissel, M. Reers, G. Dickneite, D. Hoffmann, and W. Stuber, Pharm. Res., 12, 360 (1995).
39. P. Artursson, K. Palm, and H. Lennernäs, Int. J. Pharm., 127, 103 (1996).
40. P. Artursson and J. Karlsson, Biochem. Biophys. Res. Comm., 175, 880 (1991).
41. I. J. Hildalgo, P. Bhatnagar, C.-P. Lee, J. Miller, G. Cucullino, and P. L. Smith, Pharm. Res., 12, 317 (1995).
42. S.-M. Kuo, B. Whitby, P. Artursson, and A. Ziemniak, Pharm. Res., 11, 648 (1994).
43. N. Surendran, S. O. Ugwu, L. D. Nguyen, E. J. Sterling, R. T. Dorr, and J. Blanchard, Drug Del. 2, 49 (1995).
44. U. Wenzel, I. Gebert, H. Weintraut, W.-M. Weber, W. Clauss, H. Daniel, J. Pharmacol. Exp. Therap., 277, 831 (1996).
45. J. Karlsson, and P. Artursson, Int. J. Pharm., 71, 55 (1991).
46. A. Wikman, J. Karlsson, I. Carlstedt, and P. Artursson, Pharm. Res., 10, 843 (1993).
47. I. Matthes, F. Nimmerfall, J. Vonderscher, and H. Sucker, Pharmazie, 47, 787 (1992).
48. H. H. Ussing, and K. Zerahn, Acta Physiol. Scand., 23, 110 (1951).
49. N. Jezyk, W. Rubas, and G. M. Grass, Pharm. Res., 9, 1580 (1992).
50. W. Rubas, N. Jezyk, and G. M. Grass, Pharm. Res., 10, 113 (1993).
51. A.-L. Ungell, A. Andreasson, K. Lundin, and L. Utter, J. Pharm. Sci., 81, 640 (1992).
52. N. Pantzar, S. Lundin, L. Wester, and B. R. Weström, Scand. J. Gastroenterol., 29, 703 (1994).
53. P. B. Bijlsma, R. A. Peeters, J. A. Groot, P. R. Dekker, J. A. Taminiau, and R. Van der Meer, Gastroenterology, 108, 687 (1995).
54. G. M. Grass, and S. A. Sweetana, Pharm. Res., 5-372 (1988).
55. S. C. Sutton, A. E. Forbes, R. Cargyll, J. H. Hochman, and E. L. LeCluyse, Pharm. Res., 9, 316 (1992).
56. Y. Tanaka, Y. Taki, T. Sakane, T. Nadai, H. Sezaki, and S. Yamashita, Pharm. Res., 12, 523 (1995).
57. J. Karlsson, A.-L. Ungell, and P. Artursson, Pharm. Res., 11, S248 (1994).
58. H. Lennernäs, S. Nylander, and A.-L. Ungell, Pharm. Res., 14, 667 (1997).
59. J. Blanchard, L. M. Tang, and M. E. Earle, J. Pharm. Sci., 79, 411 (1990).
60. P. J. Sinko, G. D. Leesman, and G. L. Amidon, Pharm. Res., 8, 979 (1991).
61. H. Oeschsenfurt, and D. Winne, Naynun-Schmiedeberg's Arch. Pharmacol., 264, 55 (1969).
62. W. L. Choiu, Biopharm. Drug Dispos. 16, 71 (1995).
63. P. Krugliak, D. Hollander, C. C. Schlaepfer, H. Nguyen, and T. Y. Ma, Digest. Diseases Sci. 39, 796 (1994).
64. U. Fagerholm, M. Johansson, and H. Lennernäs, Pharm. Res., 13, 1335 (1996).
65. H. G. Windmueller, A. E. Spaeth, and C. E. Ganote, Am. J. Physiol., 218, 197 (1970).
66. B. Levet-Trafit, M. S. Gruyer, M. Marjanovic, and R. C. Chou, Life Sci., 58, 359 (1996).
67. I. Komiya, J. T. Park, A. Kamani, N. F. H. Ho, and W. I. Higuchi, Int. J. Pharm., 4, 249 (1980).
68. G. L. Amidon, P. J. Sinko, and D. Fleisher, Pharm. Res., 5, 651 (1988).
69. M. R. Uhing, and R. E. Kimura, J. Clin. Invest. 95, 2790 (1995).
70. M. R. Uhing, and R. E. Kimura, J. Clin Invest. 95, 2799 (1995).
71. H. Lennernäs, Ö Ahrenstedt, R. Hallgren, L. Knutson, M. Ryde, and L. K. Paalzow, Pharm. Res., 9, 1243 (1992).
72. T. Gramatté, E. El Desoky, and U. Klotz, Eur. J. Clin. Pharmacol., 46, 253 (1994).
73. G. L. Amidon, H. Lennernäs, V. P. Shah, and J. R. Crison, Pharm. Res., 12, 413 (1995).
74. B. H. Stewart, O. H. Chan, R. H. Lu, E. L. Reyner, H. L. Schmid, H. W. Hamilton, B. A. Steinbaugh, and M. D. Taylor, Pharm. Res. 12, 693 (1995).
75. L. Zheng, J. Chen, Y. Zhu, H. Yang, W. Elmquist, and M. Hu, Pharm. Res., 11, 1771 (1994).
76. R. A. Conradi, K. F. Wilkinson, B. D. Rush, A. R. Hilgers, M. J. Ruwart, and P. S. Burton, Pharm. Res., 10, 1790 (1993).
77. H. Yuasa, D. Fleischer, and G. L. Amidon, J. Pharmacol. Exp. Therap., 269, 1107 (1994).
78. T. T. Kararli, Biopharm. & Drug Dispos. 16, 351 (1995).
79. N. Pantzar, B. R. Weström, A. Luts, S. Lundin, Scand. J. Gastroenterol., 28, 205 (1993).
80. M. Narawane, S. K. Podden, H. Bundgaard, and V. H. L. Lee, J. Drug Targeting, 1, 29 (1993).
81. R. L. Oberle, T. J. Moore, and D. A. P. Krummel, J. Pharmacol. Toxicol. Meth., 33, 75 (1995).
82. W. G. Vaughan, J. W. Horton, and P. B. Walker, J. Pediatr. Surg. 27, 968 (1992).
83. B. Polentarutti, Å Sjöberg, E.-K. Anderberg, A. Peterson, and A.-L. Ungell, Abstract CRS Meeting, Stockholm, 16-19 June, 1997.
84. A. Strocchi and M. D. Levin, Digest. Diseases and Sci., 38, 385 (1993).
85. E. J. van Hoogdalem, A. G. de Boer, and D. D. Breimer, Pharmacol. Ther., 44, 407 (1989).
86. E. S. Swenson, W. B. Milisen, and W. Curatolo, Pharm. Res., 11, 1132 (1994).
87. E. K. Anderberg, and P. Artursson, in: Drug Absorption Enhancement, (A. G. de Boer ed.), Harwood Academic Publishers, 1994, p. 101.
88. D. Winne, in: Intestinal Permeation, (M. Kramer, F. Lauterbach, eds.), Excerpta Medica, Amsterdam, 1977, p. 48.
89. S. Miyauchi, Y. Sawada, T. Iga, M. Hanano, and Y. Sugiyama, Pharm. Res., 10, 434 (1993).